Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the ovary or papillary serous carcinoma of extraovarian origin
• Recurrent or persistent following standard surgery and 1 or 2 chemotherapy regimens (with or without paclitaxel), i.e.: persistent disease or progression after chemotherapy with nodules less than the equivalent of 5 x 5 x 5 cm Recurrent carcinoma (after primary or secondary chemotherapy) detected clinically either by exam or rising CA 125 and with radiographic evidence of disease no greater than the equivalent of 5 x 5 x 5 cm nodules
• Residual disease less than 5 x 5 x 5 cm following reassessment laparotomy
• Microscopic residual disease on reassessment laparotomy after chemotherapy
• Tumor TAG-72 positive by immunoperoxidase staining of original or current tumor blocks
• At least 85% free flow of fluid in peritoneal cavity demonstrated by technetium-99m scan or other imaging within 2 weeks prior to treatment
• No evidence of disease outside the peritoneal cavity other than retroperitoneal lymphadenopathy
• No massive ascites

PATIENT CHARACTERISTICS:

• Age: 18 and over
• Performance status: ECOG 0-2
• WBC at least 3,500/mm3
• Platelet count at least 125,000/mm3
• Hemoglobin greater than 9 g/dL
• No nucleated RBC or significant teardrop RBC morphology
• Bilirubin less than 1.5 mg/dL
• AST/ALT less than 4 times normal
• Creatinine less than 2.0 mg/dL
• HIV negative
• Hepatitis B surface antigen negative
• No hypersensitivity to paclitaxel, polyoxethylated castor oil, or topotecan
• No other malignancy in past 5 years except basal cell skin carcinoma
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• At least 3 weeks since prior biologic therapy and recovered
• No prior monoclonal antibody therapy
• No concurrent immunotherapy
• No prior bone marrow or stem cell transplantation
• At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered
• No concurrent chemotherapy
• At least 3 weeks since prior radiotherapy and recovered
• No prior radiotherapy to the abdominal cavity
• No concurrent radiotherapy
• At least 3 weeks since prior major surgery and recovered
• No prior intraperitoneal therapy